Product Details
| Product Name:
Lirilumab |
CAS No.:
1000676-41-4 |
| Purity:
95.00% |
Supply Ability:
10g |
| Release date:
2026/07/07 |
Product Introduction
Bioactivity
| Name | Lirilumab |
| Description | Lirilumab (IPH2102) is an antibody against the lethal immunoglobulin-like receptor antibody KIR2D with antitumor activity that enhances the anti-HPV + cervical cancer activity of natural killer cells through VAV1-dependent NF-κB deinhibition. It can be used to study leukemia, head and neck squamous cell carcinoma (SCCHN). |
| In vivo | Treatment with Lirilumab (intravenous injection; once; 15 mg/kg) enhances the survival rate of mice injected with tumor[1]. |
| Storage | Store at low temperature
-20°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | VirusProtease | Virus Protease | ONO4483 | ONO 4483 | Lirilumab | IPH-2102 | IPH 2102 | HPV |
| Inhibitors Related | Rifampicin | Phenytoin sodium | Levofloxacin hydrochloride | Anthraquinone | L-Lysine | L-Lysine hydrochloride | Hydroxyurea | Ofloxacin | Vidarabine | Thymidine | N4-Acetylcytidine | Danthron |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
|
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States